Compound ID	CDAMM00809
Common name	Lirioresinol A
IUPAC name	4-[6-(4-hydroxy-3,5-dimethoxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-3-yl]-2,6-dimethoxyphenol
Molecular formula	C₂₂H₂₆O₈

Experimental data

Retention time	0.29
Adduct	[M+K]+
Actual mz	457.13
Theoretical mz	457.126
Error	7.97
Ionizaton mode	Positive
Instrument type	LC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score	7.1071

Identifiers and class information

Inchi key	KOWMJRJXZMEZLD-UHFFFAOYNA-N
Smiles	OC1=C(OC)C=C(C=C1OC)C2OCC3C(OCC23)C4=CC(OC)=C(O)C(OC)=C4
Superclass	Lignans, neolignans and related compounds
Class	Furanoid lignans

Plant source

Cinnamomum verum J. Presl

External sources

HMDB ID	HMDB0038928
KNApSAcK ID	C00000625
FooDB ID	FDB014720
DrugBank ID
ChEBI ID	CHEBI:49211
Pubchem Compound ID	100067
PlantCyc ID
UNPD ID	UNPD112709
Coconut ID	CNP0249408
LipidMAPS ID
NANPDB ID	NANPDB_399

Pharmacokinetic properties

Number of descriptor values(#stars)	1
Number of non-conjugated amine groups (#amine)	0
Number of amidine and guanidine groups (#amidine)	0
Number of carboxylic acid groups (#acid)	0
Number of non-conjugated amide groups (#amide)	0
Number of rotatable bonds (#rotor)	6
Number of reactive functional groups (#rtvFG)	0
Predicted central nervous system activity (CNS)	-1
Molecular weight (mol_MW)	418.443
Computed dipole moment(dipole)	6.166
Total solvent accessible surface area (SASA)	634.228
Hydrophobic component of SASA (FOSA)	448.312
Hydrophilic component of SASA (FISA)	106.35
Pie component of the SASA (PISA)	79.566
Weakly polar component of the SASA (WPSA)	0
Total solvent accesible volume (volume)	1204.73
Number of hydrogen bond donors (donorHB)	2
Number of hydrogen bond acceptors (accptHB)	7.9
Free energy of solvation of dipole (dip^2/V)	0.0315575
Index of cohesive interaction in solids (ACxDN^.5/SA)	0.0176156
Globularity descriptor (glob)	0.863337
Predicted polarizability in cubic angstroms (QPpolrz)	38.967
Predicted hexadecane/gas partition coefficient (QPlogPC16)	11.195
Predicted octanol/gas partition coefficient (QPlogPoct)	20.143
Predicted water/gas partition coefficient (QPlogPw)	11.897
Predicted octanol/water partition coefficient (QPlogPo/w)	2.846
Predicted aqueous solubility (QPlogS)	-4.08
Conformation-independent predicted aqueous solubility (CIQPlogS)	-5.348
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)	-4.123
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)	971.372
Predicted brain/blood partition coefficient (QPlogBB)	-0.749
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)	479.419
Predicted skin permeability, log Kp (QPlogKp)	-2.623
PM3 calculated ionization potential (IP(ev))	8.733
PM3 calculated electron affinity (EA(eV))	-0.216
Number of likely metabolic reactions (#metab)	10
Prediction of binding to human serum albumin (QPlogKhsa)	0.142
Predicted qualitative human oral absorption (HumanOralAbsorption)	1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)	100
Solvent-accessible surface area of fluorine atoms (SAFluorine)	0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)	0
Van der Waals surface area (PSA)	91.238
Number of nitrogen and oxygen atoms (#NandO)	8
Number of violations of Lipinski’s rule of five (RuleOfFive)	0
Number of violations of Jorgensen’s rule of three (RuleOfThree)	1

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID	Gene name	Target name	TTD_ID	Prediction source
Q07820	MCL1	Induced myeloid leukemia cell differentiation protein Mcl-1	T14912	SwissTargetPrediction
P31645	SLC6A4	Serotonin transporter (by homology)	T27812	SwissTargetPrediction
P53779	MAPK10	c-Jun N-terminal kinase 3	T85421	SwissTargetPrediction
P09917	ALOX5	Arachidonate 5-lipoxygenase	T00140	SwissTargetPrediction
P23975	SLC6A2	Norepinephrine transporter	T21945	SwissTargetPrediction
P25105	PTAFR	Platelet activating factor receptor	T87023	SwissTargetPrediction
P34972	CNR2	Cannabinoid receptor 2	T37693	SwissTargetPrediction
P31639	SLC5A2	Sodium/glucose cotransporter 2	T30085	SwissTargetPrediction
O75908	SOAT2	Acyl coenzyme A:cholesterol acyltransferase 2	T14463	SwissTargetPrediction
Q16678	CYP1B1	Cytochrome P450 1B1	T92521	SEA
Q16665	HIF1A	Hypoxia-inducible factor 1 alpha	T55610	SwissTargetPrediction
O75908	SOAT2	Acyl coenzyme A:cholesterol acyltransferase 2	T14463	SwissTargetPrediction
P51843	NR0B1	Orphan nuclear receptor DAX-1	T23191	SEA
Q8N183	NDUFAF2	HUMAN NADH:ubiquinone oxidoreductase complex assembly factor 2	T01453	SEA
Q9P0J0	NDUFA13	Mitochondrial complex I	T82391	SEA
Q9Y6M9	NDUFB9	HUMAN NADH:ubiquinone oxidoreductase subunit B9	T01465	SEA
Q8N183	NDUFAF2	HUMAN NADH:ubiquinone oxidoreductase complex assembly factor 2	T01453	SEA
P03897	MT-ND3	NADH dehydrogenase	T77195	SEA
Q02880	TOP2B	DNA topoisomerase II beta	T85733	SEA

Target associated diseases

TTD_ID	Disease_ID	Disease name	ICD_11	Uniprot ID	Gene names
T14912	DI0012	Acute myeloid leukaemia	[ICD-11: 2A60]	Q07820	MCL1
T14912	DI0245	Malignant haematopoietic neoplasm	[ICD-11: 2B33]	Q07820	MCL1
T14912	DI0250	Mature B-cell lymphoma	[ICD-11: 2A85]	Q07820	MCL1
T14912	DI0252	Melanoma	[ICD-11: 2C30]	Q07820	MCL1
T14912	DI0274	Multiple myeloma	[ICD-11: 2A83]	Q07820	MCL1
T14912	DI0391	Solid tumour/cancer	[ICD-11: 2A00-2F9Z]	Q07820	MCL1
T27812	DI0033	Anxiety disorder	[ICD-11: 6B00-6B0Z]	P31645	SLC6A4
T27812	DI0040	Attention deficit hyperactivity disorder	[ICD-11: 6A05]	P31645	SLC6A4
T27812	DI0087	Chronic pain	[ICD-11: MG30]	P31645	SLC6A4
T27812	DI0096	concerning food/fluid intake symptom	[ICD-11: MG43]	P31645	SLC6A4
T27812	DI0101	Corneal disease	[ICD-11: 9A76-9A78]	P31645	SLC6A4
T27812	DI0105	Cough	[ICD-11: MD12]	P31645	SLC6A4
T27812	DI0117	Depression	[ICD-11: 6A70-6A7Z]	P31645	SLC6A4
T27812	DI0264	Migraine	[ICD-11: 8A80]	P31645	SLC6A4
T27812	DI0301	Nicotine use disorder	[ICD-11: 6C4A]	P31645	SLC6A4
T27812	DI0308	Obesity	[ICD-11: 5B80-5B81]	P31645	SLC6A4
T27812	DI0324	Pain	[ICD-11: MG30-MG3Z]	P31645	SLC6A4
T85421	DI0125	Dissociative neurological symptom disorder	[ICD-11: 6B60]	P53779	MAPK10
T00140	DI0037	Asthma	[ICD-11: CA23]	P09917	ALOX5
T00140	DI0147	Filariasis	[ICD-11: 1F66]	P09917	ALOX5
T00140	DI0403	Thrombocytopenia	[ICD-11: 3B64]	P09917	ALOX5
T21945	DI0013	Acute pain	[ICD-11: MG31]	P23975	SLC6A2
T21945	DI0040	Attention deficit hyperactivity disorder	[ICD-11: 6A05]	P23975	SLC6A2
T21945	DI0087	Chronic pain	[ICD-11: MG30]	P23975	SLC6A2
T21945	DI0101	Corneal disease	[ICD-11: 9A76-9A78]	P23975	SLC6A2
T21945	DI0117	Depression	[ICD-11: 6A70-6A7Z]	P23975	SLC6A2
T21945	DI0166	Glaucoma	[ICD-11: 9C61]	P23975	SLC6A2
T21945	DI0264	Migraine	[ICD-11: 8A80]	P23975	SLC6A2
T21945	DI0301	Nicotine use disorder	[ICD-11: 6C4A]	P23975	SLC6A2
T21945	DI0308	Obesity	[ICD-11: 5B80-5B81]	P23975	SLC6A2
T21945	DI0324	Pain	[ICD-11: MG30-MG3Z]	P23975	SLC6A2
T21945	DI0395	Stomach cancer	[ICD-11: 2B72]	P23975	SLC6A2
T87023	DI0219	Ischaemic/haemorrhagic stroke	[ICD-11: 8B20]	P25105	PTAFR
T37693	DI0040	Attention deficit hyperactivity disorder	[ICD-11: 6A05]	P34972	CNR2
T37693	DI0214	Insomnia	[ICD-11: 7A00-7A0Z]	P34972	CNR2
T30085	DI0120	Diabetes mellitus	[ICD-11: 5A10]	P31639	SLC5A2
T30085	DI0175	Heart failure	[ICD-11: BD10-BD1Z]	P31639	SLC5A2
T30085	DI0417	Type 2 diabetes mellitus	[ICD-11: 5A11]	P31639	SLC5A2
T14463	DI0017	Adrenal cancer	[ICD-11: 2D11]	O75908	SOAT2
T55610	DI0241	Lymphoma	[ICD-11: 2A80-2A86]	Q16665	HIF1A
T55610	DI0391	Solid tumour/cancer	[ICD-11: 2A00-2F9Z]	Q16665	HIF1A
T14463	DI0017	Adrenal cancer	[ICD-11: 2D11]	O75908	SOAT2
T82391	DI0069	Cardiomyopathy	[ICD-11: BC43]	Q9P0J0	NDUFA13
T77195	DI0331	Parkinsonism	[ICD-11: 8A00]	P03897	MT-ND3
T85733	DI0062	Breast cancer	[ICD-11: 2C60-2C6Y]	Q02880	TOP2B
T85733	DI0076	Chemoprotection	[ICD-11: N.A.]	Q02880	TOP2B